Amarantus Bioscience Holdings Stock Performance
| AMBS Stock | USD 0.0001 0.00 0.00% |
Amarantus Bioscience holds a performance score of 13 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 3.94, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Amarantus Bioscience will likely underperform. Use Amarantus Bioscience variance, as well as the relationship between the potential upside and day typical price , to analyze future returns on Amarantus Bioscience.
Risk-Adjusted Performance
13 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Amarantus Bioscience Holdings are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively fragile fundamental drivers, Amarantus Bioscience unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Total Cashflows From Investing Activities | 6.1 M |
Amarantus |
Amarantus Bioscience Relative Risk vs. Return Landscape
If you would invest 0.01 in Amarantus Bioscience Holdings on September 29, 2024 and sell it today you would earn a total of 0.00 from holding Amarantus Bioscience Holdings or generate 0.0% return on investment over 90 days. Amarantus Bioscience Holdings is currently generating 21.6154% in daily expected returns and assumes 128.8322% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Amarantus, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Amarantus Bioscience Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Amarantus Bioscience's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Amarantus Bioscience Holdings, and traders can use it to determine the average amount a Amarantus Bioscience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1678
| Best Portfolio | Best Equity | AMBS | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 128.83 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average Amarantus Bioscience is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Amarantus Bioscience by adding it to a well-diversified portfolio.
Amarantus Bioscience Fundamentals Growth
Amarantus Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Amarantus Bioscience, and Amarantus Bioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Amarantus Pink Sheet performance.
| Current Valuation | 6.59 M | |||
| Shares Outstanding | 68.27 M | |||
| Price To Earning | (0.01) X | |||
| Price To Book | 53.19 X | |||
| EBITDA | (20.79 M) | |||
| Cash And Equivalents | 178 | |||
| Total Debt | 20.72 M | |||
| Debt To Equity | 0.84 % | |||
| Book Value Per Share | (0.12) X | |||
| Cash Flow From Operations | (1.8 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 3.48 M | |||
| Retained Earnings | (104.87 M) | |||
| Current Asset | 942 K | |||
| Current Liabilities | 15.83 M | |||
About Amarantus Bioscience Performance
Assessing Amarantus Bioscience's fundamental ratios provides investors with valuable insights into Amarantus Bioscience's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Amarantus Bioscience is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York. Amarantus Bioscience operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Amarantus Bioscience performance evaluation
Checking the ongoing alerts about Amarantus Bioscience for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Amarantus Bioscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Amarantus Bioscience is way too risky over 90 days horizon | |
| Amarantus Bioscience has some characteristics of a very speculative penny stock | |
| Amarantus Bioscience appears to be risky and price may revert if volatility continues | |
| Amarantus Bioscience has high likelihood to experience some financial distress in the next 2 years | |
| Amarantus Bioscience Holdings currently holds 20.72 M in liabilities with Debt to Equity (D/E) ratio of 0.84, which is about average as compared to similar companies. Amarantus Bioscience has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Amarantus Bioscience until it has trouble settling it off, either with new capital or with free cash flow. So, Amarantus Bioscience's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Amarantus Bioscience sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Amarantus to invest in growth at high rates of return. When we think about Amarantus Bioscience's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (10.58 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Amarantus Bioscience Holdings currently holds about 178 in cash with (1.8 M) of positive cash flow from operations. |
- Analyzing Amarantus Bioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Amarantus Bioscience's stock is overvalued or undervalued compared to its peers.
- Examining Amarantus Bioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Amarantus Bioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Amarantus Bioscience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Amarantus Bioscience's pink sheet. These opinions can provide insight into Amarantus Bioscience's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Amarantus Pink Sheet Analysis
When running Amarantus Bioscience's price analysis, check to measure Amarantus Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amarantus Bioscience is operating at the current time. Most of Amarantus Bioscience's value examination focuses on studying past and present price action to predict the probability of Amarantus Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amarantus Bioscience's price. Additionally, you may evaluate how the addition of Amarantus Bioscience to your portfolios can decrease your overall portfolio volatility.